33
Participants
Start Date
May 24, 2017
Primary Completion Date
December 22, 2017
Study Completion Date
June 11, 2018
GEN-003
HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP4 and glycoprotein D
Matrix-M2
Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
0.9% normal saline
Placebo
UNC Health, Chapel Hill
University of Alabama Birmingham, Birmingham
Cincinnati Children's Hospital Medical Center, Cincinnati
Tekton Research, Austin
Medical Center for Clinical Research, San Diego
Optimus Medical Group, San Francisco
NW Dermatology and Research Clinic, Portland
University of Washington, Seattle
Lead Sponsor
Genocea Biosciences, Inc.
INDUSTRY